Bamocaftor
- Generic Name
- Bamocaftor
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32F3N5O4S
- CAS Number
- 2204245-48-5
- Unique Ingredient Identifier
- 8C7XEW3K7S
- Background
Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).
A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo (matched to VX-659/TEZ/IVA)Drug: Placebo (matched to VX-659/TEZ/VX-561)Drug: TEZ/IVADrug: TEZDrug: IVA
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 124
- Registration Number
- NCT03224351
- Locations
- 🇺🇸
Rutgers-Robert Wood Johnson Medical School/ Rutgers-Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick, New Jersey, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: VX-659 Matching PlaceboDrug: Triple Combination (TC) Matching Placebos
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 163
- Registration Number
- NCT03029455
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath